---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035988"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-11-22T23:59:59+00:00"
generated_at: "2026-05-29T19:40:16.996904+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zevra launches MIPLYFFA for NPC; early adoption ahead of expectations

## Summary
- MIPLYFFA (arimoclomol) commercially available at Zevra's specialty pharmacy; first FDA-approved NPC treatment.
- Early adoption exceeded expectations; launch within 8–12 weeks post-approval as previously guided.
- Indicated in combination with miglustat for neurological NPC in patients aged 2+.
- AmplifyAssist patient support program launched to address insurance and access barriers.

## SEC filing metadata
- accession: 0001437749-24-035988
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924035988/0001437749-24-035988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924035988/zvra20241121_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035988
- JSON: https://secwatch.observer/filing/0001437749-24-035988.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.